TOP TEN perturbations for 39379_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39379_at
Selected probe(set): 212371_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39379_at (212371_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-4.114869Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.8661976Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.85674Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (fetal)
Relative Expression (log2-ratio):-2.4077377Number of Samples:4 / 2
Experimental | renal cell carcinoma study 6 (chromophobe type) |
Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
Control | normal kidney tissue (fetal) |
Normal fetal kidney tissue samples. |
precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (hyperdiploid)
Relative Expression (log2-ratio):2.3824348Number of Samples:2 / 27
Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (hyperdiploid) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG). |
precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (TEL-AML1)
Relative Expression (log2-ratio):2.3122702Number of Samples:2 / 21
Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
precursor-B-ALL study 2 (unspecified) / precursor-B-ALL study 2 (E2A-PBX1)
Relative Expression (log2-ratio):-2.150837Number of Samples:30 / 2
Experimental | precursor-B-ALL study 2 (unspecified) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (no specific subtype). Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.0861921Number of Samples:3 / 3
Experimental | tunicamycin study 2 (2ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.0608377Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):1.9712744Number of Samples:3 / 4
Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |